Atreleuton D4

Atreleuton D4 is a synthetic compound that belongs to the class of 5-lipoxygenase inhibitors. It is commonly used in pharmaceuticals as a selective inhibitor of the 5-lipoxygenase enzyme. This enzyme is responsible for the production of leukotrienes, which are inflammatory mediators involved in the pathogenesis of asthma, arthritis, and other inflammatory conditions. Atreleuton D4 works by blocking the production of leukotrienes and reducing inflammation, thereby providing relief from associated symptoms. Atreleuton D4 is typically administered orally in the form of tablets or capsules. The recommended dosage varies depending on the condition being treated and the patient's age and medical history. The drug is metabolized in the liver and excreted primarily in the urine. Chemically, Atreleuton D4 is a racemic mixture of two enantiomers, D4- and L4-atreleuton. Its molecular formula is C21H23NO3, and its molecular weight is 337.41 g/mol. The compound is a white or off-white powder that is soluble in organic solvents but insoluble in water. In addition to its anti-inflammatory properties, Atreleuton D4 has been studied for its potential use in the treatment of various other conditions, including cancer and Alzheimer's disease. However, further research is needed to validate these uses and determine their safety and efficacy.